CN111778192B - Naqu 4580 probiotics with antihypertensive activity and preparation and application thereof - Google Patents
Naqu 4580 probiotics with antihypertensive activity and preparation and application thereof Download PDFInfo
- Publication number
- CN111778192B CN111778192B CN202010704422.2A CN202010704422A CN111778192B CN 111778192 B CN111778192 B CN 111778192B CN 202010704422 A CN202010704422 A CN 202010704422A CN 111778192 B CN111778192 B CN 111778192B
- Authority
- CN
- China
- Prior art keywords
- probiotic
- narqu
- preparation
- fermentation
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 70
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 14
- 230000000529 probiotic effect Effects 0.000 claims abstract description 55
- 230000036772 blood pressure Effects 0.000 claims abstract description 30
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 9
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 7
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 6
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims description 56
- 230000004151 fermentation Effects 0.000 claims description 56
- 239000007788 liquid Substances 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 20
- 230000001954 sterilising effect Effects 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000004321 preservation Methods 0.000 claims description 10
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims description 8
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims description 8
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 238000009629 microbiological culture Methods 0.000 claims description 6
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 6
- 238000009928 pasteurization Methods 0.000 claims description 6
- 238000005086 pumping Methods 0.000 claims description 6
- 229940073490 sodium glutamate Drugs 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001603 reducing effect Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000010855 food raising agent Nutrition 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A Naqu 4580 probiotic with antihypertensive activity, a preparation and an application thereof belong to the technical field of microorganisms, and the Naqu 4580 probiotic is prepared by mixing the following components in parts by weight: s7092% -5% of Streptococcus thermophilus, L57810-20% of Lactobacillus paracasei and L55175% -88% of Lactobacillus helveticus; the Naqu 4580 probiotics has the effect of assisting in reducing blood pressure, and can be metabolized to generate small molecular substances with the blood pressure reducing activity.
Description
Technical Field
The invention belongs to the technical field of microorganisms, relates to probiotics and a preparation thereof, and particularly relates to a narqu 4580 probiotic with blood pressure reducing activity, wherein the narqu 4580 probiotic has the effect of assisting in reducing blood pressure and can be metabolized to generate a small molecular substance with the blood pressure reducing activity.
Background
Hypertension is a clinical syndrome characterized by an increase in systemic arterial blood pressure (systolic pressure and/or diastolic pressure) (systolic pressure not less than 140 mm Hg, diastolic pressure not less than 90 mm Hg), which may be accompanied by functional or organic lesions in organs such as heart, brain, kidney, etc. Hypertension is the most common chronic disease and also the most major risk factor for cardiovascular and cerebrovascular diseases. The blood pressure of a normal person fluctuates within a certain range along with the changes of internal and external environments. In the whole population, the blood pressure level gradually increases with age, the systolic pressure is more obvious, but the diastolic pressure shows a descending trend after the age of 50, and the pulse pressure is increased.
Hypertension is increasingly harming human health, and experts speculate that more than 15 hundred million hypertension patients exist in the world in 2025, so the method has important significance for developing blood pressure lowering products and has huge market potential.
Disclosure of Invention
The invention aims to provide a narqu 4580 probiotic and a preparation thereof, which can help to improve blood pressure and can effectively reduce the blood pressure of a human body. Meanwhile, the invention also provides a preparation method of the narcotine 4580 probiotic preparation and application of the narcotine 4580 probiotic preparation in the aspect of assisting in reducing blood pressure.
The technical scheme adopted by the invention for realizing the purpose is as follows:
a nadroph 4580 probiotic with antihypertensive activity is prepared by mixing the following components in parts by weight: s7092% -5% of Streptococcus thermophilus, L57810-20% of Lactobacillus paracasei and L55175% -88% of Lactobacillus helveticus; the Streptococcus thermophilus (Streptococcus thermophilus) S709 is preserved in the China general microbiological culture Collection center with the preservation number of CGMCC NO.18028, Lactobacillus paracasei (Lactobacillus paracasei) L578, is preserved in the China general microbiological culture Collection center with the preservation number of CGMCC NO.15603 and has the preservation date of 2018, 4 months and 11 days; the Lactobacillus helveticus L551 is preserved in the China general microbiological culture Collection center of China Committee for culture Collection of microorganisms with the preservation number of CGMCC NO.15604 and the preservation date of 2018, 4 months and 11 days.
Use of narcotine 4580 probiotic in the preparation of a food product for the adjuvant treatment of blood pressure or hypertension.
Use of a narcotine 4580 probiotic formulation in the preparation of a food product for the adjuvant treatment of blood pressure or hypertension.
Furthermore, the food comprises a food prepared by taking the narqu 4580 probiotic preparation as a main medicine active ingredient or taking the narqu 4580 probiotic preparation as an auxiliary material.
Further, the food is prepared from a preparation of the narcotine 4580 probiotics and a pharmaceutically acceptable carrier.
Furthermore, the formulation of the narqu 4580 probiotic preparation is any one of powder, granules, emulsion, tablets, blocks, rods and oral liquid.
Further, the oral liquid is the narcotine 4580 probiotic fermentation liquid.
Further, the powder or the oral liquid is prepared by the following method:
a. mixing materials: adding culture medium into the material dissolving tank, adding 10-30g/L sodium glutamate, stirring for 10-15min, and maintaining the temperature of the material liquid at 55-60 deg.C;
b. and (3) sterilization: sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 15-20 min;
c. fermentation: b, inoculating the narcotile 4580 probiotics to the feed liquid treated in the step b for fermentation, wherein the fermentation temperature is 37-45 ℃, and the fermentation temperature is 28-35 h;
d. stirring in a fermentation tank when the pH value of the fermentation is 4.4-4.6, controlling the rotating speed to be 100 and 300rpm/min, and sterilizing or not sterilizing to obtain the narqu 4580 probiotic fermentation liquor;
e. d, obtaining the narqu 4580 probiotic fermentation liquor which is the oral liquid;
or, carrying out deep-cooling granulation and freeze-drying on the narqu 4580 probiotic fermentation liquor obtained in the step d to obtain a probiotic mixed preparation narqu 4580 freeze-dried powder, namely powder;
or, spraying powder on the narqu 4580 probiotic fermentation liquor obtained in the step d and drying to obtain the narqu 4580 probiotic preparation, namely powder.
The invention has the beneficial effects that:
the Naqu 4580 probiotics have the effect of assisting in reducing blood pressure and can be metabolized to generate small molecular substances with the blood pressure reducing activity. The Naqu 4580 probiotics have obvious effect of improving the blood pressure quality of a human body.
The Nagqu4580 probiotic preparation (namely the Naqu 4580 probiotic preparation) has good acid resistance, can grow well under the environment condition of pH3.0, can generate high-content gamma-aminobutyric acid, antihypertensive peptide substances, tryptophan, chlorogenic acid, lactic acid, acetic acid, citric acid, tartaric acid and the like, and can cause cerebral vasodilatation through a GABAA receptor on the surface of a cortical cerebral blood vessel, so that the blood pressure is reduced; on the other hand, gamma-aminobutyric acid and antihypertensive peptide can inhibit the activity of Angiotensin Converting Enzyme (ACE), thereby achieving the effect of lowering blood pressure.
Drawings
Figure 1 is a graph of the gamma aminobutyric acid content of Nagqu4580 probiotic formulations.
Detailed Description
The present invention will be further described with reference to the following examples. The Nagqu4580 probiotic preparation (namely the Nagqu4580 probiotic preparation) capable of reducing blood pressure is provided by the invention, the Nagqu4580 probiotic preparation is prepared by fermenting Nagqu4580 fermenting agent, the fermenting agent is provided by Hebei Yiran Biotechnology Co., Ltd, and the Nagqu4580 fermenting agent is Nagqu4580 probiotic. In the present invention, the raw materials and equipment used are commercially available or commonly used in the art, unless otherwise specified. The methods in the following examples are conventional in the art unless otherwise specified. The streptococcus thermophilus, the lactobacillus paracasei and the lactobacillus helveticus used in the invention are all the existing strains of the hebei Yiran biotechnology limited company.
Detailed description of the preferred embodiments
The Nagqu4580 probiotic preparation can be oral liquid or powder, and the preparation method comprises the following steps:
preparing oral liquid:
a. mixing materials: adding conventional culture medium into a material dissolving tank, adding 10-30g/L sodium glutamate, dissolving and stirring for 10-15min, and keeping the temperature of the material liquid at 55-60 ℃;
b. and (3) sterilization: sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 15-20 min;
c. fermentation: b, inoculating a Nagqu4580 leavening agent (provided by Hebeiyi Biotechnology limited, namely Naqu 4580 probiotics) to the material liquid treated in the step b for fermentation, wherein the fermentation temperature is 37-45 ℃, and the fermentation temperature is 28-35 h;
d. stirring in a fermentation tank when the pH value of the fermentation is 4.4-4.6, and optionally sterilizing at high temperature to obtain the Naqu 4580 probiotic fermentation liquid, namely the oral liquid.
Preparation of powder:
a. mixing materials: adding conventional culture medium into a material dissolving tank, adding 10-30g/L sodium glutamate, dissolving and stirring for 10-15min, and keeping the temperature of the material liquid at 55-60 ℃;
b. and (3) sterilization: sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 15-20 min;
c. fermentation: b, inoculating a Nagqu4580 leavening agent (provided by Hebeiyi Biotechnology Co., Ltd.) to the feed liquid treated in the step b for fermentation, wherein the fermentation temperature is 37-45 ℃, and the fermentation temperature is 28-35 h;
d. stirring in a fermentation tank when the pH value of the fermentation is 4.4-4.6, and optionally sterilizing at high temperature to obtain a narqu 4580 probiotic fermentation liquid;
e. and (3) carrying out cryogenic granulation (dripping liquid bacteria liquid into liquid nitrogen, instantly cooling to-193 ℃), and freeze-drying (vacuumizing and freeze-drying at the temperature of-20 to-70 ℃) to obtain the Nagqu4580 probiotic powder preparation.
The powder can also be prepared by the following method:
a. mixing materials: adding conventional culture medium into a material dissolving tank, adding 10-30g/L sodium glutamate, dissolving and stirring for 10-15min, and keeping the temperature of the material liquid at 55-60 ℃;
b. and (3) sterilization: sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 15-20 min;
c. fermentation: b, inoculating a Nagqu4580 leavening agent (provided by Hebeiyi Biotechnology Co., Ltd.) to the feed liquid treated in the step b for fermentation, wherein the fermentation temperature is 37-45 ℃, and the fermentation temperature is 28-35 h;
d. stirring in a fermentation tank when the pH value of the fermentation is 4.4-4.6, and optionally sterilizing at high temperature to obtain a narqu 4580 probiotic fermentation liquid;
e. spraying and drying (high pressure pump pressure 13-19Mpa, air inlet temperature 162-.
Example 1
a. Mixing materials: adding MRS culture medium into a material dissolving tank, then adding 30g/L sodium glutamate, dissolving and stirring for 15min, and keeping the temperature of the material liquid at 55 ℃;
b. and (3) sterilization: sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 115 ℃, and the time is 20 min;
c. fermentation: b, inoculating a Nagqu4580 leavening agent (provided by Hebeiyi Biotechnology Co., Ltd.) to the feed liquid treated in the step b for fermentation, wherein the fermentation temperature is 37 ℃ and the fermentation temperature is 35 hours;
d. stirring in a fermentation tank when the pH value of the fermentation is 4.4 to obtain a narqu 4580 probiotic fermentation liquid;
e. and (3) carrying out cryogenic granulation (dripping the narqu 4580 probiotic fermentation liquid into liquid nitrogen, instantly cooling to-193 ℃), and freeze-drying (carrying out vacuum freeze-drying at-70 ℃) to obtain the Nagqu4580 probiotic preparation.
Second, Performance test
1. Example 1 determination of the content of gamma-aminobutyric acid in a Nagqu4580 probiotic formulation
(1) And the method adopts high performance liquid chromatography for determination, and comprises the following steps:
preparing a mobile phase: mobile phase A: 50% -60% acetonitrile;
mobile phase B: ammonium acetate in water (20-30 mM);
detection conditions are as follows: a chromatographic column: agilent C18.
(2) And the result of the detection
Detecting by high performance liquid chromatography, and detecting the content of gamma-aminobutyric acid at 76-90mg/g with reference to figure 1.
2. Example 1Nagqu4580 probiotic formulation antihypertensive activity assay optimization
The detection of the antihypertensive peptide active substance was carried out by a spectrophotometer method as follows:
1) adding 100-200 mul of Hip-His-Leu solution of 2-5mmol/L and 50-100 mul of the mixed preparation sample of the Naqu 4580 probiotics of the invention into a test tube, and preserving the heat for 1-3min at 35-37 ℃;
2) adding 10-20 μ l of ACE solution, mixing, and keeping the temperature at 35-37 deg.C for 15-30 min;
3) adding 200-;
4) adding 1-1.7ml of ethyl acetate, shaking and mixing uniformly for 10-15s, and centrifuging (3000-4000r/min for 15-20 min);
5) sucking 0.5-1.0ml of ethyl acetate layer by a pipette, evaporating to dryness in an oven at 100-120 ℃ for 20-30min, and dissolving in 1-3ml of deionized water again;
6) the absorbance was measured at 228 nm.
The captopril antihypertensive drug is used as a control group, and the antihypertensive activity is detected, wherein the detection result is as follows:
the invention shows that products capable of generating ACE inhibitory peptide activity are produced by using the narqu 4580 probiotics, and certain development and popularization prospects are shown. The experiment only carries out preliminary discussion on the development of the antihypertensive product, aims to promote the development and utilization of probiotics and the development of functional food and bring benefits to human beings.
3. The Nagqu4580 probiotic preparation in the embodiment 1 of the invention is taken at a dosage of 0.5-2 g/day by a human body every day and is taken 0.5-1 hour before sleeping.
The narqu 4580 probiotics can generate antihypertensive active substances, and the narqu 4580 probiotic preparation product contains bacteria and is also accompanied with antihypertensive active substance components, so that the bacteria can reach the intestinal tract to achieve the purpose of reducing blood pressure, and the antihypertensive active substances can directly enter blood through the intestinal tract to achieve the purpose of quickly inhibiting ACE enzyme, and the possibility of assisting blood pressure reduction is achieved.
The research of the invention is based on the experimental verification that the edible lactobacillus conforming to food carries out the experiment verification, the blood pressure reducing active substance generated by metabolism has the inhibiting effect on ACE enzyme (vasoconstriction and blood pressure rise caused by activity increase) causing hypertension, and the verification based on the experimental basis can possibly play a certain role in assisting the blood pressure reduction.
Claims (7)
1. The narqu 4580 probiotics with the antihypertensive activity is characterized by being prepared by mixing the following components in parts by weight: streptococcus thermophilus (Streptococcus thermophilus) S7092% -5%, lactobacillus paracasei (L.paracasei) (L.paracasei)Lactobacillus paracasei) L57810-20%, Lactobacillus helveticus (L57810-20%)Lactobacillus helveticus) L55175% -88%; said Streptococcus thermophilus (Streptococcus thermophilus) S709 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC NO.18028 and lactobacillus paracasei (C.), (Lactobacillus paracasei) L578, deposited in China general microbiological culture Collection center (CGMCC) with a preservation number of CGMCC NO.15603 and a preservation date of 2018, 4 months and 11 days; said Lactobacillus helveticus bacterium (A), (B), (CLactobacillus helveticus) L551, preserved in China general microbiological culture Collection center, with the preservation number of CGMCC NO.15604 and the preservation date of 2018, 4 months and 11 days.
2. Use of the narcotine 4580 probiotic of claim 1 in the preparation of a food product to assist in lowering blood pressure.
3. Use of a narcotine 4580 probiotic formulation according to claim 1 in the manufacture of a food product for the assistance of lowering blood pressure.
4. The use of a narqu 4580 probiotic formulation as claimed in claim 3 in the preparation of a food product for assisting in lowering blood pressure, wherein the food product comprises a food product having a narqu 4580 probiotic formulation as the main active ingredient, or a food product having a narqu 4580 probiotic formulation as an ingredient.
5. The use of the narqu 4580 probiotic preparation according to claim 3 in the preparation of foods for assisting in lowering blood pressure, wherein the narqu 4580 probiotic preparation is in the form of any one of powder, granules, emulsion, tablets, blocks, bars and oral liquid.
6. The use of a narqu 4580 probiotic formulation according to claim 5 in the preparation of a food product for assisting in lowering blood pressure, wherein the oral liquid is a narqu 4580 probiotic fermented liquid.
7. The use of the narqu 4580 probiotic formulation according to claim 5 in the preparation of a food product for assisting in lowering blood pressure, wherein the powder or oral liquid is prepared by the following method:
a. mixing materials: adding culture medium into the material dissolving tank, adding 10-30g/L sodium glutamate, stirring for 10-15min, and maintaining the temperature of the material liquid at 55-60 deg.C;
b. and (3) sterilization: sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 15-20 min;
c. fermentation: b, inoculating the narcotile 4580 probiotics to the feed liquid treated in the step b for fermentation, wherein the fermentation temperature is 37-45 ℃, and the fermentation temperature is 28-35 h;
d. stirring in a fermentation tank when the pH value of the fermentation is 4.4-4.6, controlling the rotating speed to be 100 and 300rpm/min, and sterilizing or not sterilizing to obtain the narqu 4580 probiotic fermentation liquor;
e. d, obtaining the narqu 4580 probiotic fermentation liquor which is the oral liquid;
or, carrying out deep-cooling granulation and freeze-drying on the narqu 4580 probiotic fermentation liquor obtained in the step d to obtain a probiotic mixed preparation narqu 4580 freeze-dried powder, namely powder;
or, spraying powder on the narqu 4580 probiotic fermentation liquor obtained in the step d and drying to obtain the narqu 4580 probiotic preparation, namely powder.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910665448.8A CN110331108A (en) | 2019-07-23 | 2019-07-23 | A kind of probiotics mix preparation Nagqu 4580 (Nagqu 4580) and its application with antihypertensive activity |
| CN2019106654488 | 2019-07-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111778192A CN111778192A (en) | 2020-10-16 |
| CN111778192B true CN111778192B (en) | 2021-11-23 |
Family
ID=68147120
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910665448.8A Pending CN110331108A (en) | 2019-07-23 | 2019-07-23 | A kind of probiotics mix preparation Nagqu 4580 (Nagqu 4580) and its application with antihypertensive activity |
| CN202010704422.2A Active CN111778192B (en) | 2019-07-23 | 2020-07-21 | Naqu 4580 probiotics with antihypertensive activity and preparation and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910665448.8A Pending CN110331108A (en) | 2019-07-23 | 2019-07-23 | A kind of probiotics mix preparation Nagqu 4580 (Nagqu 4580) and its application with antihypertensive activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110331108A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113755357A (en) * | 2020-06-04 | 2021-12-07 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus preparation and application thereof |
| CN112501089A (en) * | 2021-01-20 | 2021-03-16 | 山东中科嘉亿生物工程有限公司 | Lactobacillus paracasei JLPF-131 for improving hypertension and application thereof in preparation |
| CN113142304A (en) * | 2021-03-29 | 2021-07-23 | 河北一然生物科技有限公司 | Probiotic composition for promoting human body metabolism to generate yellow feces and application thereof |
| CN113088474B (en) * | 2021-05-13 | 2022-03-04 | 河北一然生物科技股份有限公司 | Microbial combined leavening agent and preparation method and application thereof |
| CN113699067B (en) * | 2021-08-24 | 2023-05-26 | 杭州娃哈哈科技有限公司 | Lactobacillus helveticus, high-yield GABA (gamma-amino acid) direct vat set and application thereof |
| CN113892651A (en) * | 2021-10-08 | 2022-01-07 | 河北一然生物科技股份有限公司 | Novel application of composite probiotic preparation in antioxidant field |
| CN114752525B (en) * | 2022-04-21 | 2022-09-09 | 广西壮族自治区水牛研究所 | Lactobacillus casei with blood pressure lowering effect and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105368738A (en) * | 2015-10-23 | 2016-03-02 | 中国农业大学 | Lactobacillus paracasei and appliance thereof |
| CN109517763A (en) * | 2018-12-27 | 2019-03-26 | 内蒙古农业大学 | Lactobacillus helveticus H11 and its application |
-
2019
- 2019-07-23 CN CN201910665448.8A patent/CN110331108A/en active Pending
-
2020
- 2020-07-21 CN CN202010704422.2A patent/CN111778192B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105368738A (en) * | 2015-10-23 | 2016-03-02 | 中国农业大学 | Lactobacillus paracasei and appliance thereof |
| CN109517763A (en) * | 2018-12-27 | 2019-03-26 | 内蒙古农业大学 | Lactobacillus helveticus H11 and its application |
Non-Patent Citations (1)
| Title |
|---|
| 那曲4580-款专业、独特乳酸菌饮品研发;道客巴巴;《道客巴巴》;20180813;摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110331108A (en) | 2019-10-15 |
| CN111778192A (en) | 2020-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111778192B (en) | Naqu 4580 probiotics with antihypertensive activity and preparation and application thereof | |
| CN112322528B (en) | Lactobacillus rhamnosus capable of intervening metabolic syndrome and application thereof | |
| CN108208853A (en) | A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method | |
| WO2010110374A1 (en) | Agent for enhancing hypoglycemic activity | |
| CN112553117B (en) | Lactobacillus reuteri capable of inhibiting skin stratum corneum thickening and application thereof | |
| CN112999261A (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
| WO2016049879A1 (en) | Uses of bacteroides in treatment or prevention of obesity-related diseases | |
| CN116731891B (en) | Bifidobacterium breve B2798 and application thereof in preparation of probiotic preparation | |
| JP4874532B2 (en) | Sleep improver | |
| CN1916028A (en) | Polysaccharide outside cyst of lactobacillus casei and crude product, prepartion method and application | |
| CN105919113A (en) | Method for preparing lucid ganoderma and soybean enzyme through microbial fermentation | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN109498744A (en) | A kind of preparation method that composite bacteria fermentation compound eucommia bark leaf is scattered | |
| JP5571650B2 (en) | Drugs for non-alcoholic fatty liver disease and / or non-alcoholic steatohepatitis | |
| CN115322940B (en) | Lactobacillus plantarum and sleep-aiding and anti-depression product and application thereof | |
| US20230413836A1 (en) | Method for Preparing Tibetan Kefir Grain and Gynostemma Pentaphyllum Fermentation Milk with Blood Pressure Lowering Effect | |
| CN114588248B (en) | Composition for preventing and treating alcohol cancer and preparation method thereof | |
| CN103653107A (en) | Preparation method of probiotic fermented kiwi fruit juice | |
| CN113621673B (en) | Method for fermenting ginseng by composite strain, fermentation product and application | |
| CN112675288A (en) | Traditional Chinese medicine enzyme and preparation method thereof | |
| KR101982223B1 (en) | METHOD FOR PREPARING OLIGOSACCHARIDES USING Leuconostoc lactis CCK940 | |
| JP2004201598A (en) | Fermented product and method for producing the same | |
| JP7371191B1 (en) | Use of Streptococcus salivarius subsp. thermophilus ST7 fermented composition to improve exercise performance and reduce sarcopenia | |
| TWI838036B (en) | Manufacturing method for increasing the total content of nmn and cell antioxidant capability | |
| CN113100442B (en) | Royal jelly tortoise turtle peptide chewing tablet and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No.16, bangxiu East Road, North District, Zhengding high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Applicant after: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. Address before: 050000 Hebei Yiran Biotechnology Co., Ltd Applicant before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 050800 No. 16, bangxiu East Road, North District, high tech Industrial Development Zone, Zhengding County, Zhengding District, China (Hebei) pilot Free Trade Zone, Shijiazhuang City, Hebei Province Applicant after: Hebei Yiran Biotechnology Co.,Ltd. Address before: No.16, bangxiu East Road, North District, Zhengding high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Applicant before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |